Table 1 Clinical and molecular characteristics of patients who underwent ALKi therapy
From: Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis
Patient ID | Age | Gender | Primary tumor site | Histology | Stage at diagnosis | Surgery/locoregional treatment | Lines of systemic treatment before ALKi | ALK fusion partner | MSI/MSS status | Other NGS data | First-Line ALKi agent | Best tumor response | First-Line ALKi PFS (months) | Further ALKi agent (PFS[months]) | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P1 | 53 | Female | Right colon | Adenocarcinoma | IV | Surgery | 1 | CAD-ALK | NA | TP53 p.R248W | Entrectinib | CR | 4.5 | None | |
P2 | 70 | Female | Right colon | Adenocarcinoma | IV | None | 2 | EML4-ALK | MSS | TP53 R157H、AKT1、ANNKRD11、BRAF、DNMT3A、FLT4、GABRA6、PTPRT、RBM10、SLX4 | Crizotinib | PR | 3 | Alectinib (0.5 months), Lorlatinib (11.5 months) | |
P3 | 87 | Female | Right colon | Adenocarcinoma | IV | Surgery | 3 | STRN-ALK | MSI | KRAS R164Q、STK11、TP53、AEID1A、BCOR、CDH2、MLL2、MLL3、PAX5、RAD50 | Ceritinib | PR | 9 | None | |
P4 | 53 | Female | Right colon | Adenocarcinoma | IV | None | 2 | CAD-ALK | MSS | ALK 1196Q、TP53 R273C | Alectinib | CR | 3.8 | None | |
P5 | 46 | Male | Rectum | Adenocarcinoma | IV | None | 2 | EML4-ALK | MSS | KDR, SMAD4, APC, TP53 | Crizotinib | PD | 2.3 | None | |
P6 | 45 | Male | Right colon | Adenocarcinoma | IV | None | 2 | EML4-ALK | MSS | TP53 splice site, APC truncating mutation | Crizotinib | PR | 9.1 | Alectinib (NA) | |
P7 | 51 | Female | Right colon | Adenocarcinoma | IV | None | 2 | CAD-ALK | MSS | TP53 | Crizotinib | SD | 3.7 | Alectinib (NA) | |
P8 | 50 | Female | Right colon | Adenocarcinoma | IV | Surgery | 2 | CAD-ALK | NA | Ensartinib | PR | 4.6 | None | ||
P9 | 67 | Male | Left colon | Adenocarcinoma | IV | Surgery | 1 | STRN-ALK | MSS | TP53, PIK3CG, PTPRS, PTPRT, MYC | Alectinib | SD | 14 | Ceritinib (NA) | |
C5 | 43 | Male | Right colon | Adenocarcinoma | III | Surgery | 2 | EML4-ALK | MSS | PIK3R2 p.R717H;TP53 p.L43*;LRP1B p.K1100R;WIPF1 p.G216R；NUDCD1-RSPO2Fusion | Ensartinib | PR | 5.8 | Brigatinib (3 months); Lorlatinib (2 months) | – |
C6 | 77 | Female | Left colon | Signet-ring cell | IV | None | 1 | SRSF7-ALK | MSS | MSH6 p.F1088fs；TP53 c.75-1G>C | Alectinib | SD | 1.9 | None | – |
